breaking

Novo Nordisk Targets International Expansion for Wegovy Pill as Weight-Loss Market Goes Global

Novo Nordisk plans to expand its Wegovy pill internationally beginning later this year, pending regulatory approvals, as weight-loss drug competition extends beyond U.S. borders.

The U.S. market currently represents more than half of sales for both Novo and rival Eli Lilly. The Danish drugmaker said it will prioritize expansion based on patient demand, physician expertise, and telehealth infrastructure availability.

Telehealth partnerships are being used as distribution channels. In Germany, telehealth has helped patients access obesity treatments in convenient ways. Novo did not specify which countries would receive first-wave launches but indicated the strategy would reflect market potential.

The expansion marks a significant shift in competitive dynamics. Eli Lilly forecasts 28% sales growth this year, while Novo projects a 4% to 12% decline despite recent guidance increases.